Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQXYE9)

Drug Name
PD-158780 Drug Info
Synonyms
171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; PD 158780; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl-
Cross-matching ID
PubChem CID
4707
ChEBI ID
CHEMBL53753
CAS Number
CAS 171179-06-9
TTD Drug ID
D03ATU

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.13 0.00e+0 93/133 (69.92%) NDUFA3;COX5B;ATP6V0E1;...
Valine, leucine and isoleucine degradation 1.98 3.75e-3 42/48 (87.5%) MCCC1;PCCA;ACAA2;...
Thermogenesis 1.98 2.50e-3 173/232 (74.57%) NDUFA3;COX5B;ATP5MC2;...
Cardiac muscle contraction 1.86 1.88e-2 64/87 (73.56%) TNNC1;ACTC1;COX5B;...
Other glycan degradation 1.84 1.50e-2 13/18 (72.22%) GLB1;ENGASE;HEXA;...
Histidine metabolism 1.79 2.63e-2 16/22 (72.73%) ALDH3A1;MAOA;AOC1;...
Pentose and glucuronate interconversions 1.76 3.32e-2 17/34 (50%) AKR1B10;UGT2A3;GUSB;...
Glyoxylate and dicarboxylate metabolism 1.74 4.03e-2 23/30 (76.67%) SHMT1;SHMT2;PCCA;...
Ascorbate and aldarate metabolism 1.71 4.33e-2 15/30 (50%) UGT2A3;ALDH3A2;GUSB;...
Glycine, serine and threonine metabolism 1.69 4.80e-2 31/40 (77.5%) MAOA;PHGDH;GATM;...
Salmonella infection -1.67 2.84e-2 198/249 (79.52%) TUBB;MAP2K4;ARPC1B;...
Th17 cell differentiation -1.68 2.73e-2 95/107 (88.79%) CD3G;IL6ST;HLA-DQA1;...
Th1 and Th2 cell differentiation -1.68 2.78e-2 80/92 (86.96%) CD3G;HLA-DQA1;STAT5B;...
Cytosolic DNA-sensing pathway -1.69 2.70e-2 52/63 (82.54%) POLR3K;POLR3D;POLR2F;...
Adherens junction -1.69 2.62e-2 63/71 (88.73%) SMAD4;CTNNA2;SNAI1;...
Proteasome -1.70 2.67e-2 44/46 (95.65%) PSMD3;PSMD14;PSMA5;...
Bladder cancer -1.74 1.91e-2 40/41 (97.56%) EGF;MMP1;NRAS;...
DNA replication -1.74 1.88e-2 34/36 (94.44%) MCM4;MCM7;POLD1;...
Human T-cell leukemia virus 1 infection -1.74 1.85e-2 197/219 (89.95%) BCL2L1;SMAD4;PPP3R1;...
Kaposi sarcoma-associated herpesvirus infection -1.75 1.88e-2 172/193 (89.12%) GNG5;NRAS;GNG12;...
Malaria -1.75 1.98e-2 44/50 (88%) HBB;SELP;GYPA;...
Osteoclast differentiation -1.75 1.95e-2 117/127 (92.13%) TGFBR1;FOS;IKBKB;...
Yersinia infection -1.78 1.44e-2 120/137 (87.59%) PLCG1;MAP2K3;ARPC3;...
MAPK signaling pathway -1.80 1.38e-2 272/294 (92.52%) HSPA6;CACNG3;MAP3K11;...
Inflammatory bowel disease -1.80 1.47e-2 58/65 (89.23%) RELA;STAT1;IL22;...
Ribosome biogenesis in eukaryotes -1.80 1.32e-2 52/108 (48.15%) TBL3;IMP3;FBL;...
Legionellosis -1.80 1.41e-2 51/57 (89.47%) ITGAM;CD14;CXCL2;...
Pyrimidine metabolism -1.82 1.24e-2 40/56 (71.43%) DCTPP1;NME6;RRM1;...
Epithelial cell signaling in Helicobacter pylori infect... -1.83 1.24e-2 62/70 (88.57%) ATP6V0B;MAP2K4;TJP1;...
AGE-RAGE signaling pathway in diabetic complications -1.83 1.24e-2 97/100 (97%) COL4A2;TGFB2;CCL2;...
NF-kappa B signaling pathway -1.83 1.36e-2 90/104 (86.54%) CHUK;CCL4;TRAF1;...
NOD-like receptor signaling pathway -1.84 1.51e-2 145/181 (80.11%) RELA;MAPK11;STAT1;...
Tuberculosis -1.85 1.70e-2 159/180 (88.33%) RELA;SYK;MAPK11;...
C-type lectin receptor signaling pathway -1.87 1.59e-2 93/104 (89.42%) CCL17;PPP3R1;IL2;...
TNF signaling pathway -1.88 1.85e-2 103/112 (91.96%) MAP2K4;CHUK;TRAF1;...
Amoebiasis -1.92 7.42e-3 99/102 (97.06%) GNA11;IFNG;COL4A6;...
Rheumatoid arthritis -1.93 9.27e-3 78/93 (83.87%) ATP6V0A2;MMP1;IFNG;...
Leishmaniasis -1.94 1.24e-2 67/77 (87.01%) RELA;MAPK11;STAT1;...
Hematopoietic cell lineage -2.06 6.18e-3 90/99 (90.91%) CD3E;HLA-DRB1;HLA-DPA1;...
IL-17 signaling pathway -2.18 0.00e+0 84/94 (89.36%) IL13;MMP1;IFNG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H